Literature DB >> 2669930

Marked erythropoietin increase before fall in Hb after treatment with cytostatic drugs suggests mechanism other than anaemia for stimulation.

G Birgegård1, L Wide, B Simonsson.   

Abstract

Serum erythropoietin (Epo) was measured in 23 patients before, during and after intensive cytostatic treatment courses for acute leukaemia or before bone marrow transplantation. A marked increase was seen in all patients, starting 1 or 2 d after initiation of treatment. A peak was reached after about 7 d, at levels as high as 1450 IU/l, after which Epo fell rapidly, even in patients who were anaemic at that time. In 13 of the patients there was no fall in Hb level that could explain the increase in Epo. The increase was too large to be explained by an altered Epo metabolism or marrow utilization. Cytostatic drugs cause an increase in Epo production not mediated through anaemia, possibly initiated by a cytostatic effect on the kidneys or by an unknown stimulatory factor, responsive to bone marrow inhibition.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2669930     DOI: 10.1111/j.1365-2141.1989.tb07733.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  12 in total

1.  Plasma erythropoietin concentrations in patients receiving intensive platinum or nonplatinum chemotherapy.

Authors:  R Canaparo; F Casale; E Muntoni; G P Zara; C Della Pepa; E Berno; N Pons; G Fornari; M Eandi
Journal:  Br J Clin Pharmacol       Date:  2000-08       Impact factor: 4.335

Review 2.  Regulation of erythropoietin production.

Authors:  Wolfgang Jelkmann
Journal:  J Physiol       Date:  2010-11-15       Impact factor: 5.182

3.  Serum erythropoietin level: relationships to blood hemoglobin concentration and erythrocytic activity of the bone marrow.

Authors:  W Jelkmann; G Wiedemann
Journal:  Klin Wochenschr       Date:  1990-04-17

4.  Effect of iron on erythropoietin production in anaemic piglets.

Authors:  O V Sjaastad; T Framstad; A K Blom
Journal:  Acta Vet Scand       Date:  1996       Impact factor: 1.695

5.  Serum erythropoietin level in anemic cancer patients.

Authors:  M Ozguroglu; B Arun; G Demir; F Demirelli; N M Mandel; E Buyukunal; S Serdengecti; B Berkarda
Journal:  Med Oncol       Date:  2000-02       Impact factor: 3.064

6.  Effects of chemotherapeutic and immunosuppressive drugs on the production of erythropoietin in human hepatoma cultures.

Authors:  M Wolff; W Jelkmann
Journal:  Ann Hematol       Date:  1993-01       Impact factor: 3.673

Review 7.  The role of iron supplementation during epoietin treatment for cancer-related anemia.

Authors:  M Hedenus; G Birgegård
Journal:  Med Oncol       Date:  2008-05-13       Impact factor: 3.064

Review 8.  Hematopoietic growth factors and the treatment of tumor-associated anemias.

Authors:  U Dührsen; D K Hossfeld
Journal:  Ann Hematol       Date:  1994-11       Impact factor: 3.673

Review 9.  Inadequate erythropoietin response to anemia: definition and clinical relevance.

Authors:  G Barosi
Journal:  Ann Hematol       Date:  1994-05       Impact factor: 3.673

10.  Thrombopoietin expands erythroid progenitors, increases red cell production, and enhances erythroid recovery after myelosuppressive therapy.

Authors:  K Kaushansky; V C Broudy; A Grossmann; J Humes; N Lin; H P Ren; M C Bailey; T Papayannopoulou; J W Forstrom; K H Sprugel
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.